News

Big pharma stocks like AbbVie (NYSE: ABBV) usually aren't high on the list that investors look to for opportunities that could make them into millionaires. After all, they aren't typically in the

The biotechnology industry is getting more attention than usual following a buyout offer for Alpine Immune Sciences (NASDAQ: ALPN) from Vertex Pharmaceuticals (NASDAQ: VRTX).

Vertex recently offered

Income-seeking investors have to make an important choice when shopping for stocks to buy. Shares of companies that are likely to raise their dividend payouts at a rapid pace tend to offer low

Pfizer (NYSE: PFE) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare

Vertex Pharmaceuticals (NASDAQ: VRTX) has a promising healthcare business with many growth opportunities ahead. But with the stock such a hot buy over the past few years and its valuation now

Amgen (NASDAQ: AMGN) is one of the top drugmakers in the world, with a market value north of $140 billion. The company has been expanding its business via acquisitions in recent years as it looks to

Pfizer (NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) looks unstoppable. In the past six months, the company launched a brand-new and highly promising product on the market and delivered positive

Later this year, the Federal Reserve is projected to begin reducing interest rates. While the exact number of rate cuts is still uncertain, this regulatory action is expected to stimulate a surge in

One of the hottest themes in the pharmaceutical industry right now is weight loss. Medications specifically approved for weight loss, such as Wegovy and Zepbound, are taking the industry by storm.

If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made

If you're building a stream of dividend income to fuel your retirement dreams, it helps to fill your portfolio with businesses that can keep growing through a wide range of economic conditions

Two adages capture the dilemma investors face when they consider buying a beaten-down stock:

These well-known sayings seem to be contradictory. However, they're not when taken in the correct

The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure

Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its

No pair of companies dominated the COVID-19 vaccine market quite like Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA). Both saw their revenue and earnings skyrocket, along with their share prices, as

A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine -- and Pfizer

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the S&P 500 in the past three, five, and 10 years. That's not a fluke: The drugmaker has been highly successful financially while

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.

Three Motley Fool contributors believe they've identified three

Few things are more satisfying than watching a steadily growing stream of passive income flow into your brokerage account. If you've been holding back from investing because you think you can't

Cathie Wood and high dividend yields go together like... well, it's hard to finish that sentence because they don't go together at all. Wood and her Ark Invest funds are known for investing in

Does a rising tide really lift all boats? We could soon find out if the adage applies to the stock market.

A bull market is now well underway. The S&P 500 has soared more than 30% over the last 12

Investors looking for stocks that can deliver heaps of passive income might want to turn their heads toward the healthcare sector. Right now, there are a couple of beaten-down stocks offering

Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue